Guggenheim Maintains Buy on Damora Therapeutics, Raises Price Target to $60
Damora Therapeutics Inc DMRA
$20.66
▲ +1.92%
(+$0.39)
Open
$20.80
Prev Close
$20.27
Day Range
$19.80 – $20.80
52W Range
$16.50 – $34.89
Market Cap
$1.28B
Beta
-4.15
EPS (TTM)
$-141.43
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-10-29 |
| Shares Out. | 61,550,000 |
| Website | galecto.com/ ↗ |
| Phone | 13026587581 |
| Employees | 7 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$31.2M |
| Free Cash Flow | -$44.5M |
| Total Assets | $543.6M |
| Total Liabilities | $27.6M |
| Equity | $516.1M |
About Damora Therapeutics Inc
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
Damora Therapeutics Inc is a publicly traded company under the ticker symbol DMRA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-09-01)